ATRA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ATRA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.
As of today (2024-12-14), Atara Biotherapeutics's Volatility is 79.81%.
For the Biotechnology subindustry, Atara Biotherapeutics's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's Volatility distribution charts can be found below:
* The bar in red indicates where Atara Biotherapeutics's Volatility falls into.
The annualized volatility is calculated as following:
σA | = | σM | * | √12 |
= | √ 1/(n-1) ∑(Ri - R')^2 | * | √12 |
Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Atara Biotherapeutics (NAS:ATRA) Volatility Explanation
Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.
Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.
Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.
Thank you for viewing the detailed overview of Atara Biotherapeutics's Volatility provided by GuruFocus.com. Please click on the following links to see related term pages.
Jill Henrich | officer: EVP, Global Head RA & Quality | 2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS CA 91320 |
Anhco Nguyen | officer: EVP, Chief Sci. & Tech Officer | 2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS CA 91320 |
Eric J Hyllengren | officer: SVP, CFO | 2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS CA 91320 |
Amar Murugan | officer: SVP, GC & Secretary | C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BOULEVARD,SUITE 900, SOUTH SAN FRANCISCO CA 94080 |
Pascal Touchon | director, officer: President and CEO | C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BOULEVARD SUITE 900, SOUTH SAN FRANCISCO CA 94080 |
Manher Joshi | officer: EVP, Chief Medical Officer | 2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS CA 91320 |
Carol Giltner Gallagher | director | C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005 |
Eric Dobmeier | director | C/O SAETTLE GENETICS INC, 21823 30TH DRIVE SE, BOTHELL WA 98021 |
William K Heiden | director | C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451 |
Charlene A. Banard | officer: EVP, Chief Technical Officer | C/O APPLIED MOLECULAR TRANSPORT INC., 450 EAST JAMIE COURT, SOUTH SAN FRANCISCO CA 94080 |
Jakob Dupont | officer: EVP, Head of R&D | C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063 |
Utpal Koppikar | officer: Chief Financial Officer | C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO CA 94080 |
Ameet Mallik | director | C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102 |
Kristin Yarema | officer: Chief Commercial Officer | C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD., SUITE 900, SOUTH SAN FRANCISCO CA 94080 |
Joe Newell | officer: Chief Tech. Operations Officer | C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO CA 94080 |
From GuruFocus
By Business Wire • 11-13-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By Business Wire • 10-04-2024
By Business Wire • 06-05-2024
By Business Wire • 06-21-2024
By Business Wire • 09-03-2024
By Business Wire • 11-12-2024
By GuruFocus Research • 02-06-2024
By Business Wire • 09-04-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.